- Home
- ZTO vs CANF Comparison
ZTO vs CANF Comparison
Compare ZTO & CANF Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ZTO
- CANF
- Stock Information
- Founded
- ZTO 2002
- CANF 1994
- Country
- ZTO China
- CANF Israel
- Employees
- ZTO N/A
- CANF N/A
- Industry
- ZTO Advertising
- CANF Biotechnology: Pharmaceutical Preparations
- Sector
- ZTO Consumer Discretionary
- CANF Health Care
- Exchange
- ZTO Nasdaq
- CANF Nasdaq
- Market Cap
- ZTO 13.4B
- CANF 14.8M
- IPO Year
- ZTO 2016
- CANF N/A
- Fundamental
- Price
- ZTO $18.05
- CANF $1.02
- Analyst Decision
- ZTO Buy
- CANF Strong Buy
- Analyst Count
- ZTO 5
- CANF 2
- Target Price
- ZTO $22.64
- CANF $14.00
- AVG Volume (30 Days)
- ZTO 1.4M
- CANF 146.1K
- Earning Date
- ZTO 08-19-2025
- CANF 08-29-2025
- Dividend Yield
- ZTO 3.88%
- CANF N/A
- EPS Growth
- ZTO N/A
- CANF N/A
- EPS
- ZTO 1.22
- CANF N/A
- Revenue
- ZTO $6,230,576,589.00
- CANF $674,000.00
- Revenue This Year
- ZTO $16.57
- CANF $461.72
- Revenue Next Year
- ZTO $12.82
- CANF N/A
- P/E Ratio
- ZTO $14.78
- CANF N/A
- Revenue Growth
- ZTO 14.76
- CANF N/A
- 52 Week Low
- ZTO $16.34
- CANF $0.98
- 52 Week High
- ZTO $27.50
- CANF $4.69
- Technical
- Relative Strength Index (RSI)
- ZTO 56.00
- CANF 39.13
- Support Level
- ZTO $17.55
- CANF $0.99
- Resistance Level
- ZTO $17.89
- CANF $1.09
- Average True Range (ATR)
- ZTO 0.25
- CANF 0.04
- MACD
- ZTO 0.11
- CANF -0.00
- Stochastic Oscillator
- ZTO 76.12
- CANF 16.67
About ZTO ZTO Express (Cayman) Inc. each representing one ordinary share.
ZTO Express is China's largest express delivery company by parcel volume, with a volume share of 22.1% in 2022. It operates a network partner model where it provides line-haul transportation and sorting services, while its local network partners provide first-mile pickup and last-mile delivery services under the ZTO brand name. Headquartered in Shanghai, the company was founded in 2002 by Meisong Lai, who remains chair, CEO, and its major shareholder with 77% voting rights as of June 30, 2023. ZTO's strategic shareholder is leading China e-commerce company Alibaba Group with around an 11.7% interest.
About CANF Can-Fite Biopharma Ltd Sponsored ADR (Israel)
Can Fite Biofarma Ltd is an clinical-stage biopharmaceutical company. The company develops orally bioavailable small molecule therapeutic products for the treatment of cancer, liver and inflammatory diseases and erectile dysfunction. The company's platform technology utilizes the Gi protein associated A3 adenosine receptor, or A3AR, as a therapeutic target. The company's drug candidate, Piclidenoson, is currently in a Phase III trial for psoriasis. Can-Fite's liver drug, Namodenoson, is headed into a Phase III trial for hepatocellular carcinoma (HCC), the common form of liver cancer, and a Phase IIb trial for the treatment of non-alcoholic steatohepatitis (NASH).